It takes a long time to extract apoA-I from human plasma; various genetic variants of apoA-I or recombinant apoA-I have been developed to be able to replace apoA-I from human plasma to obtain reconstituted HDL nanoparticles or HDL designed to protect against atherosclerosis similar to HDL itself. This evidence concerns the gene APOA1 and atherosclerosis.